A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive BCell Acute Lymphoblastic Leukemia

被引：1
|
作者：
Short, Nicholas J. [1 ]
Kantarjian, Hagop [1 ]
Alvarado, Yesid [1 ]
Burger, Jan A. [1 ]
Jain, Nitin [1 ]
Konopleva, Marina [1 ]
Ravandi, Farhad [1 ]
DiNardo, Courtney D. [1 ]
Masarova, Lucia [1 ]
Sasaki, Koji [1 ]
Thompson, Philip A. [1 ]
Ferrajoli, Alessandra [1 ]
Jacob, Jovitta [1 ]
Milton, Anna [1 ]
Garris, Rebecca [1 ]
Jabbour, Elias J. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-154124
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2299
引用
收藏
页数：6
相关论文
共 50 条
  • [1] A Phase II Study of Inotuzumab Ozogamicin for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
    Senapati, Jayastu
    Short, Nicholas
    Alvarado, Yesid
    Burger, Jan A.
    Jain, Nitin
    Konopleva, Marina
    Ravandi, Farhad
    DiNardo, Courtney D.
    Masarova, Lucia
    Sasaki, Koji
    Thompson, Philip A.
    Ferrajoli, Alessandra
    Jacob, Jovitta
    Mayor, Ejiroghene
    Milton, Anna
    Loiselle, Christopher
    Garris, Rebecca
    Kantarjian, Hagop
    Jabbour, Elias
    BLOOD, 2022, 140 : 3253 - 3255
  • [2] Phase 2 study of inotuzumab ozogamicin for measurable residual disease in acute lymphoblastic leukemia in remission
    Jabbour, Elias
    Haddad, Fadi G.
    Short, Nicholas J.
    Senapati, Jayastu
    Jain, Nitin
    Sasaki, Koji
    Jorgensen, Jeffrey
    Wang, Sa A.
    Alvarado, Yesid
    Wang, Xuemei
    Dinardo, Courtney
    Masarova, Lucia
    Kadia, Tapan
    Garris, Rebecca S.
    Ravandi, Farhad
    Kantarjian, Hagop
    BLOOD, 2024, 143 (05) : 417 - 421
  • [3] A Phase II Study of Blinatumomab for the Treatment of Measurable Residual Disease-Positive B-Cell Acute Lymphoblastic Leukemia
    Haddad, Fadi
    Kantarjian, Hagop
    Short, Nicholas J.
    Konopleva, Marina
    Jain, Nitin
    Ravandi, Farhad
    Daver, Naval
    Alvarado, Yesid
    Takahashi, Koichi
    Garcia-Manero, Guillermo
    Velasquez, Michelle
    Garris, Rebecca
    Jabbour, Elias J.
    BLOOD, 2021, 138
  • [4] Inotuzumab ozogamicin in the treatment of acute lymphoblastic leukemia
    Dahl, Jenny
    Marx, Kayleigh
    Jabbour, Elias
    EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (04) : 329 - 334
  • [5] Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
    Tvito, Ariella
    Rowe, Jacob M.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2017, 17 (12) : 1557 - 1564
  • [6] Inotuzumab ozogamicin for the treatment of acute lymphoblastic leukemia
    Savoy, J. Michael
    Welch, Mary Alma
    Nasnas, Patrice E.
    Kantarjian, Hagop
    Jabbour, Elias
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (12) : 347 - 356
  • [7] Inotuzumab ozogamicin (INO) for the treatment of measurable residual disease (MRD) in patients with B-cell acute lymphoblastic leukemia (B-ALL): Results from a phase II study
    Nasr, Lewis Fady
    Short, Nicholas James
    Senapati, Jayastu
    Valero, Yesid Alvarado
    Jain, Nitin
    Konopleva, Marina
    Macaron, Walid
    Ravandi, Farhad
    Dinardo, Courtney Denton
    Sasaki, Koji
    Ferrajoli, Alessandra
    Nasnas, Cedric Christophe
    Zoghbi, Marianne
    Jacob, Jovitta
    Mayor, Ejiroghene
    Milton, Anna
    Loiselle, Christopher
    Garris, Rebecca
    Kantarjian, HagopM.
    Jabbour, Elias
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [8] Treatment of adult acute lymphoblastic leukemia with inotuzumab ozogamicin
    Paul, Shilpa
    Rausch, Caitlin R.
    Kantarjian, Hagop
    Jabbour, Elias J.
    FUTURE ONCOLOGY, 2017, 13 (25) : 2233 - 2242
  • [9] Inotuzumab ozogamicin in the treatment of B-cell acute lymphoblastic leukemia
    Thomas, Xavier
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2012, 21 (06) : 871 - 878
  • [10] Profile of inotuzumab ozogamicin and its potential in the treatment of acute lymphoblastic leukemia
    Thomas, Xavier
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2014, 4 : 1 - 8
12345